GLP-1 Receptor Agonist Treatment Improves Fasting and Postprandial Lipidomic Profiles Independently of Diabetes and Weight Loss
G Della Pepa, BG Patrício, F Carli, S Sabatini… - Diabetes, 2024 - diabetesjournals.org
Treatment with glucagon-like peptide 1 receptor agonists reduces liver steatosis and
cardiometabolic risk (CMR). Few data are available on lipid metabolism, and no information …
cardiometabolic risk (CMR). Few data are available on lipid metabolism, and no information …